Localisation of AMPK γ subunits in cardiac and skeletal muscles
- First Online:
- Cite this article as:
- Pinter, K., Grignani, R.T., Watkins, H. et al. J Muscle Res Cell Motil (2013) 34: 369. doi:10.1007/s10974-013-9359-4
- 817 Views
The trimeric protein AMP-activated protein kinase (AMPK) is an important sensor of energetic status and cellular stress, and mutations in genes encoding two of the regulatory γ subunits cause inherited disorders of either cardiac or skeletal muscle. AMPKγ2 mutations cause hypertrophic cardiomyopathy with glycogen deposition and conduction abnormalities; mutations in AMPKγ3 result in increased skeletal muscle glycogen. In order to gain further insight into the roles of the different γ subunits in muscle and into possible disease mechanisms, we localised the γ2 and γ3 subunits, along with the more abundant γ1 subunit, by immunofluorescence in cardiomyocytes and skeletal muscle fibres. The predominant cardiac γ2 variant, γ2-3B, gave a striated pattern in cardiomyocytes, aligning with the Z-disk but with punctate staining similar to T-tubule (L-type Ca2+ channel) and sarcoplasmic reticulum (SERCA2) markers. In skeletal muscle fibres AMPKγ3 localises to the I band, presenting a uniform staining that flanks the Z-disk, also coinciding with the position of Ca2+ influx in these muscles. The localisation of γ2-3B- and γ3-containing AMPK suggests that these trimers may have similar functions in the different muscles. AMPK containing γ2-3B was detected in oxidative skeletal muscles which had low expression of γ3, confirming that these two regulatory subunits may be co-ordinately regulated in response to metabolic requirements. Compartmentalisation of AMPK complexes is most likely dependent on the regulatory γ subunit and this differential localisation may direct substrate selection and specify particular functional roles.
KeywordsAMPKγ SubunitsSub-cellular localisationCardiomyopathy
Mutations in PRKAG2 have been shown to cause cardiac hypertrophy with associated glycogen deposition, Wolff-Parkinson-White syndrome and conduction abnormalities (Blair et al. 2001; Gollob et al. 2001; Arad et al. 2002; Kim et al. 2009). All reported mutations are within the nucleotide-binding domain, and functional studies have suggested both that the basal level of activity is increased (Hamilton et al. 2001) and that nucleotide binding is lower or even abolished in the mutant protein resulting in impairment of AMPK activation (Steinberg and Kemp 2009). Interestingly, there is a reported mutation (R225Q) in γ3 occurring naturally in pig (Milan et al. 2000) and in human (R225W) (Costford et al. 2007); these mutations cause increased glycogen deposition in skeletal muscle in both cases, probably via increased glucose uptake rather than decreased glycogen utilisation (Andersson 2003). The amino acid affected by the γ3 mutation occupies the same position within the first CBS domain as the R302Q γ2 mutation.
The precise subcellular localisation of AMPK complexes within muscle cells is unclear. The β2 isoform, and hence trimers containing this subunit, was localized in the M-line in muscle fibres (Ponticos et al. 1998). In a different study, it was demonstrated that α1/γ1-containing AMPK is found in the Z-disk, apparently mediated by interaction of γ1 with plectin (Gregor et al. 2006), suggesting that, at least in this case, the regulatory subunit is responsible for AMPK compartmentalisation. In support of this, our work using human umbilical vein endothelial cells (HUVECs) also suggests that the γ subunit appears to determine AMPK localisation (Pinter et al. 2012b). Furthermore, selective activation of α2/β2/γ3 AMPK complexes during exercise has been reported in skeletal muscle and this was suggested to be due to the subcellular localisation of this AMPK complex, possibly directed by γ3 (Birk and Wojtaszewski 2006). Cell fractionation of mouse heart tissue found that all AMPK γ2 proteins were retained in the cytoskeletal fraction (Pinter et al. 2012a), suggesting a possible sarcomeric localisation. A yeast two-hybrid screen of a human heart cDNA library identified cardiac troponin I as an interactor with amino acids 1–273 of γ2-long, indicating that AMPK with γ2 is associated with the thin filaments (Oliveira et al. 2012).
As several different γ subunit isoforms and variants can and indeed are expressed in a cell (Cheung et al. 2000; Lang et al. 2000; Pinter et al. 2012a), we hypothesize that the different AMPK complexes have different functions, and function depends on their subcellular localisation that may be determined by the γ subunit. We have already demonstrated that AMPK complexes with distinct subunit compositions are compartmentalised and assigned for different cellular functions (Pinter et al. 2012b). In this study we provide further support for this notion by using immunofluorescence technique and detecting differential localisation of AMPK complexes with different γ subunits in mouse cardiomyocytes and in skeletal muscle fibres.
Animals and tissue collection
Immunofluorescent staining and confocal microscopy
Isolated mouse ventricular cardiomyocytes in cell suspension were spun onto poly-Lys-coated slides in a Statspin cytofuge (600 rpm, 2 min). Cells were fixed in 4 % PFA and permeabilized in 0.2 % Triton-PBS for 30 min. Blocking was carried out with 5 % BSA in PBS.
Bundles of skeletal muscle fibres were teased out in relaxing solution (10 mM EGTA, 5.6 mM MgCl2, 100 mM KCl, 20 mM imidazole, 5 mM ATP, pH 7.0; supplied with 10 mM creatine phosphate and 500 U/ml creatine kinase) onto poly-Lys-coated slides. Air-dried slides were rehydrated in PBS, then fixed and treated similarly to cardiomyocytes. Primary antibodies: rabbit anti-γ2 (γ2C—C-terminal), 1:60 dilution (gift from D. Carling); rabbit anti-γ2-3B (G2-3B), 1:50 (Pinter et al. 2012a); rabbit anti-γ2-long (G2-L), 1:50 [polyclonal antibody G2-L was raised in rabbit against the KHL-conjugated peptide 1-20 of γ2-long (MDTKKKKEVSSPGGSSGKKN-C) by Harlan UK (Hillcrest)]; rabbit AMPKγ3 (D-22) (Santa Cruz), 1:50 dilution; goat AMPKγ1 (T-20), 1:50 dilution (Santa Cruz); mouse anti-myomesin, 1:30 dilution (gift from E. Ehler); mouse monoclonal anti-α-actinin (EA53), 1:500 dilution (Sigma); goat L-type Ca2+ CP α1D (E-19), 1:50 dilution (Santa Cruz); goat SERCA2 (N-19), 1:50 dilution (Santa Cruz); mouse monoclonal anti-slow myosin heavy chain (BA-F8), 1:500 dilution (DSHB). Primary antibodies were usually applied overnight at 4 °C.
The appropriate fluorescent conjugated secondary antibodies (Alexa Fluor Molecular Probes) were used in 1:400 dilution; both the primary and the secondary antibodies were diluted in 5 % BSA/PBS. When it was possible, double staining was carried out. Cells were mounted using SlowFade®Gold antifade reagent with DAPI (Invitrogen), however the nuclei were actually stained and imaged with To-Pro3/DNA (Invitrogen) and coloured in blue. Imaging was performed with a Leica TSC SP5 confocal laser-scanning microscope with a 63×, 1.4NA objective.
Use of AMPKγ antibodies to localise AMPK complexes
AMPK is a trimeric complex and the subunits are not known to have any role as isolated proteins; therefore by detecting the γ subunits the subcellular localisation of the holoenzyme can be monitored. Differential localization of the γ2 protein variants is rather challenging. All γ2 variants share the entire sequence of γ2-short (Fig. 1) and therefore γ2-short cannot be selectively detected with antibodies. The available γ2 antibodies either recognise all three variants (if raised against sequence within the common nucleotide-binding region) or one (or both) of the longer forms (if raised against N-terminal sequences). The epitopes recognised by the three antibodies used in this study are mapped in Fig. 1. Antibody γ2C is a pan-γ2 antibody, with the immunogen being a short peptide at the C-terminus of all γ2 proteins; we have raised G2-L against the N-terminal peptide of 20 amino acids, and it exclusively detects γ2-long; and G2-3B, that only recognises γ2-3B (Pinter et al. 2012a).
Localisation of AMPKγ isoforms in mouse cardiomyocytes
The γ1 protein was present in the Z-disk (Fig. 3B). This is consistent with the earlier report of its localisation in differentiated mouse myotubes, possibly recruited by binding plectin, a Z-disk component (Gregor et al. 2006). No nuclear staining was observed with the γ1 antibody in cardiomyocytes.
Localisation of AMPKγ isoforms in mouse skeletal muscles
We have previously detected γ3 expression in the developing mouse heart; this declines after birth and appears to be “replaced” by γ2-3B expression (Pinter et al. 2012a). The γ subunit “switch” seems to coincide with metabolic changes: the embryonic heart is mainly glycolytic while the adult heart is oxidative. We therefore tested whether the oxidative skeletal muscle fibres contained AMPK γ2-3B. When EDL or white quadriceps fibres were stained with the γ2-3B antibody, we detected, though infrequently, fibres that were stained with γ2-3B antibody; the staining pattern was similar to the γ3 staining (Fig. 5A). In contrast, the occurrence of γ2-3B-stained fibres in soleus muscle was higher and imaging is shown in Fig. 5B. The pattern of γ2-3B staining resembles that of γ3 (see enlarged segment, Fig. 5B), suggesting that the two subunits occupy similar positions. No γ2-3B staining was detected in the nuclei (Fig. 5A). Interestingly, skeletal myopathy has been observed in patients with PRKAG2 mutations (Murphy et al. 2005); ragged red fibres with excess mitochondria were detected but skeletal muscle biopsies of patients presented little glycogen accumulation.
In mouse cardiomyocytes, the predominant AMPK γ2 protein, γ2-3B, was shown to give patchy Z-disk staining and was also found in the nuclei. The punctate Z-disk staining was similar to the T-tubule and SR markers, L-type Ca2+ channel and SERCA2 respectively. Staining with a pan-γ2 antibody suggested additional M-line localisation of either the γ2-short or γ2-long variants; the latter was confirmed with a γ2-long-specific antibody. Since the affinity of the γ2C antibody is the same for each γ2 protein, the higher staining intensity in the Z-disk may reflect the presence of the γ2-short, which is the second most abundant γ2 protein in cardiomyocytes after γ2-3B (Pinter et al. 2012a). The AMPK γ2 variants thus appear to localize to different sarcomeric positions in cardiomyocytes.
Our earlier work has shown that AMPK can phosphorylate cardiac troponin I, both in vitro and in vivo, and that this phosphorylation modulates the myofilament Ca2+-sensitivity (Oliveira et al. 2012). This finding was initiated by the identification of the interaction of cardiac troponin I with a fragment containing the N-terminal 273 amino acids of AMPK γ2-long by Yeast-Two-Hybrid screening of a human cardiac cDNA library. However, γ2-long and γ2-3B have a common segment in their N-terminal extension, and since there is much more γ2-3B protein than γ2-long in cardiomyocytes (Pinter et al. 2012a), that function may be linked to AMPK containing γ2-3B. Given that there is no apparent staining throughout the I band, it is possible that AMPK is recruited to phosphorylate cardiac troponin I and mobilised from its position around the Z-disk upon activation.
The γ1 protein was localised at the Z-disk in cardiomyocytes. AMPK with the γ1 isoform is known to be anchored by plectin to the Z-disk in differentiated myocytes (Gregor et al. 2006) and our observation is consistent with this. The γ2-short, similarly to γ1, only contains the nucleotide-binding domain and the highly conserved segment close to its N-terminus to where the β subunit binding-site was localised (Viana et al. 2007). We have reported that γ2-short is largely replaced by γ1 during cardiogenesis (Pinter et al. 2012a), suggesting partially or entirely overlapping function for the two proteins and that may support the Z-disk localisation of γ2-short. Interestingly, the Z-disk staining with the γ1 antibody resembles the subcellular positions of glycogen synthase (GS) that is regulated by AMPK (Prats et al. 2005; Bendayan et al. 2009); glycogen particles are also linked to the cytoskeleton and so are the glycogen-metabolising enzymes (Gregor et al. 2006; Graham et al. 2010). Therefore it is plausible to presume that AMPK with γ1 is involved in the regulation of glycogen metabolism along with AMPK containing the γ2-short subunit.
Both γ2-3B and γ3, in cardiac and skeletal muscle respectively, are present along the Z-disk and in the I band; both staining patterns closely resemble the respective T-tubule/SR structures. The different appearance of γ2-3B and γ3 staining reflects the structural differences of the T-tubules/SR structures in cardiac and skeletal muscle. In cardiomyocytes, the T-tubules are aligned with the Z-disk but a set of two T-tubules, flanking the Z-disk is present in the I band of skeletal muscle sarcomeres. In cardiac muscle, the arrangement of the terminal cisternae of SR is not as regular as in skeletal muscle, therefore diads flanking the Z-disk are formed instead of triads. The structure of the T-tubule system is also complex, with irregular branching in heart (Soeller and Cannell 1999).
Given their apparently common T-tubule/SR localisation, is there any indication that AMPK with γ2-3B or γ3 have similar functions? A point mutation in γ3 causes glycogen accumulation in skeletal muscle; the cause of this is not the activation of glycogen synthase or decreased glycogen utilization but increased glucose uptake (Andersson 2003). This mutation is in the first CBS domain, in the exact position as one of the γ2 mutations is; the consequence of the γ2 mutation is glycogen deposition in cardiac tissue (Gollob et al. 2001; Gollob 2003). The embryonic heart is more glycolytic but becomes more oxidative during differentiation; in parallel, there is an apparent switch from γ3 to γ2-3B expression in the developing heart (Pinter et al. 2012a). Glucose transport is mainly mediated by GLUT1 and GLUT4 in cardiomyocytes (Stanley et al. 1997) and myocardial AMPK activation and subsequent GLUT-4 translocation to the sarcolemma was reported in rat (Russell et al. 1999). The sodium/glucose cotransporter (SGLT1) is also expressed in heart (Banerjee et al. 2009) and AMPK activation was also reported to trigger the increased membrane translocation of SGLT1 (Sopjani et al. 2010).
In skeletal muscle, α2/β2/γ3 complexes become preferentially activated during exercise (Birk and Wojtaszewski 2006); α2-AMPK was identified as an endoplasmic reticulum (ER) stress suppressor as its activation maintains SERCA activity and intracellular Ca2+ homeostasis (Dong et al. 2010). The expression γ3 is restricted to glycolytic fast fibres; oxidative fibres (slow or fast) seem to contain γ2-3B. Mitochondria are tethered to the SR in both skeletal muscle fibres and in cardiomyocytes (Boncompagni et al. 2009) where we detected γ2-3B. It has been reported that AMPK phosphorylates PGC1α and instead of affecting the mitochondrial oxidative capacity it stimulate mitochondrial biogenesis (Jager et al. 2007). A PRKAG2 mutation was shown to cause myopathy in red muscle (Murphy et al. 2005) and ragged red fibres were observed with mitochondria accumulation but without substantial glycogen deposition. This observation also supports our finding that γ2-3B is only expressed in oxidative muscle (cardiomyocytes, slow type I and fast type II skeletal muscle fibres), however we have not done the thorough fibre type matching.
Furthermore, several ion channels are regulated by AMPK, some of them by direct phosphorylation (reviewed by Andersen and Rasmussen 2012). In a recent study AMPK phosphorylation of the voltage-gated Kv2.1K-channel was demonstrated in neurons, where AMPK activation reduced excitability to conserve energy (Ikematsu et al. 2011). Kv2.1 is present in all part of the transverse and axial tubule system in cardiomyocytes (O’Connell et al. 2008). Ion channel down-regulation by AMPK has been reported; one of them is the KCNQ1 potassium channel. KCNQ1 ubiqutination is promoted by AMPK activation via the ubiqutin-protein ligase, Nedd4-2 in kidney cells (Alzamora et al. 2010). KCNQ1 is expressed in cardiomyocytes, where its abnormal trafficking was linked to hereditary long QT syndrome (Wilson et al. 2005). AMPK associated with the T-tubules may regulate ion transport, contributing perhaps to conductive irregularities that accompany cardiac hypertrophy caused by PRKAG2 mutations.
In summary, we have demonstrated AMPK compartmentalisation in cardiomyocytes and in skeletal muscle fibres and showed that differential localisation of the different AMPK complexes is most likely governed by the regulatory subunits, either by the different γ isoforms or by the variants of γ2. By compartmentalisation, the different AMPK complexes are most probably assigned different functions. Mutation in the γ2 proteins would alter these functions; as a consequence, this could trigger mechanisms to cause the different aspects of the cardiac disease (hypertrophy, conductive disorder, glycogen deposition). However, further studies needed to understand the importance and the dynamics of the compartmentalisation of the γ2-AMPK complexes, focusing on specific interactions in each location. The need for isoform-selective activation of AMPK to develop cardioprotective therapies has been highlighted in a recent review article (Kim and Tian 2011) and protein–protein interaction studies could result in new drug designs that acts specifically on γ2-AMPK complexes to ameliorate the disease caused by the PRKAG2 mutations.
We thank Henrik Isackson for the preparation of skeletal muscle fibres. This work was supported by the British Heart Foundation and the Wellcome Trust Functional Genomics Initiative. R. T. Grignani was sponsored by the MBBS-PhD Programme (Agency for Science, Technology and Research, Singapore and School of Medicine, National University Singapore).
Conflict of interest
Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.